Total Payments
$514,722
2024 Payments
$92,668
Companies
23
Transactions
487
Medicare Patients
375
Medicare Billing
$48,836
Payment Breakdown by Category
Other$379,506 (73.7%)
Consulting$80,474 (15.6%)
Travel$39,621 (7.7%)
Food & Beverage$10,890 (2.1%)
Research$3,411 (0.7%)
Education$819.90 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $378,785 | 149 | 73.6% |
| Consulting Fee | $80,474 | 39 | 15.6% |
| Travel and Lodging | $39,621 | 71 | 7.7% |
| Food and Beverage | $10,890 | 173 | 2.1% |
| Unspecified | $3,411 | 44 | 0.7% |
| Education | $819.90 | 10 | 0.2% |
| Grant | $721.00 | 1 | 0.1% |
Payments by Type
General
$511,311
443 transactions
Research
$3,411
44 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ViiV Healthcare Company | $311,086 | 229 | $0 (2024) |
| Janssen Products, LP | $152,669 | 123 | $0 (2023) |
| Gilead Sciences, Inc. | $22,464 | 32 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $20,966 | 7 | $0 (2023) |
| GlaxoSmithKline, LLC. | $2,918 | 16 | $0 (2023) |
| Merck Sharp & Dohme LLC | $1,999 | 17 | $0 (2024) |
| ABBVIE INC. | $1,026 | 5 | $0 (2024) |
| Lupin Inc. | $668.82 | 8 | $0 (2024) |
| Janssen Biotech, Inc. | $307.58 | 16 | $0 (2021) |
| Shionogi Inc | $124.55 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $92,668 | 85 | ViiV Healthcare Company ($88,598) |
| 2023 | $89,433 | 84 | ViiV Healthcare Company ($41,406) |
| 2022 | $39,942 | 45 | ViiV Healthcare Company ($27,584) |
| 2021 | $31,976 | 30 | ViiV Healthcare Company ($23,310) |
| 2020 | $48,479 | 35 | ViiV Healthcare Company ($42,195) |
| 2019 | $104,962 | 77 | ViiV Healthcare Company ($75,385) |
| 2018 | $61,587 | 71 | Janssen Products, LP ($52,255) |
| 2017 | $45,674 | 60 | Janssen Products, LP ($36,252) |
All Payment Transactions
487 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: HIV | ||||||
| 12/19/2024 | Gilead Sciences, Inc. | Vemlidy (Drug) | Consulting Fee | Cash or cash equivalent | $2,660.00 | General |
| Category: HBV | ||||||
| 12/17/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $124.74 | General |
| Category: HIV | ||||||
| 12/16/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: HIV | ||||||
| 12/05/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: HIV | ||||||
| 12/02/2024 | ViiV Healthcare Company | DOVATO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $975.00 | General |
| Category: HIV | ||||||
| 11/25/2024 | Apotex Inc. | ADEFOVIR DIPIVOXIL (Drug), EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, LAMIVUDINE | — | In-kind items and services | $14.34 | Research |
| Study: Antiretroviral Pregnancy Registry (APR) • Category: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor | ||||||
| 11/24/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $24.95 | General |
| 11/21/2024 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $5,850.00 | General |
| 11/14/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $103.42 | General |
| Category: HIV | ||||||
| 11/07/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $132.32 | General |
| Category: HIV | ||||||
| 11/06/2024 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $5,208.41 | General |
| 11/06/2024 | ViiV Healthcare Company | — | Consulting Fee | Cash or cash equivalent | $5,200.00 | General |
| 10/31/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $48.16 | General |
| 10/31/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $41.28 | General |
| 10/31/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $22.70 | General |
| 10/30/2024 | ViiV Healthcare Company | — | Travel and Lodging | In-kind items and services | $191.82 | General |
| 10/25/2024 | ABBVIE INC. | NORVIR (Drug) | Consulting Fee | Cash or cash equivalent | $623.82 | General |
| Category: VIROLOGY | ||||||
| 10/25/2024 | ABBVIE INC. | NORVIR (Drug) | Consulting Fee | Cash or cash equivalent | $358.58 | General |
| Category: VIROLOGY | ||||||
| 10/25/2024 | Dr.Reddy's Laboratories,Inc. | DARUNAVIR (Drug), DARUNAVIR, DARUNAVIR | — | Cash or cash equivalent | $24.95 | Research |
| Study: Antiretroviral Pregnancy Registry (APR) • Category: Allergy and Immunology | ||||||
| 10/25/2024 | Lupin Inc. | DARUNAVIR (Drug) | — | Cash or cash equivalent | $24.95 | Research |
| Study: Antiretroviral Pregnancy Registry (APR) • Category: HIV treatment | ||||||
| 10/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $14.34 | General |
| 10/25/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $14.34 | General |
| 10/25/2024 | Dr.Reddy's Laboratories,Inc. | DARUNAVIR (Drug), DARUNAVIR, DARUNAVIR | — | Cash or cash equivalent | $14.34 | Research |
| Study: Antiretroviral Pregnancy Registry (APR) • Category: Allergy and Immunology | ||||||
| 10/25/2024 | Mylan Inc. | — | — | In-kind items and services | $14.34 | Research |
| Study: Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women. (APR) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL | GlaxoSmithKline, LLC. | $1,606 | 6 |
| A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF | GlaxoSmithKline, LLC. | $1,312 | 10 |
| Antiretroviral Pregnancy Registry APR | Lupin Inc. | $129.55 | 2 |
| Antiretroviral Pregnancy Registry | Teva Pharmaceuticals USA, Inc. | $80.94 | 6 |
| Antiretroviral Pregnancy Registry (APR) | Lupin Inc. | $68.02 | 4 |
| Antiretroviral Pregnancy Registry (APR) | Apotex Inc. | $39.29 | 2 |
| Antiretroviral Pregnancy Registry (APR) | Dr.Reddy's Laboratories,Inc. | $39.29 | 2 |
| Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant Women. (APR) | Mylan Inc. | $39.29 | 2 |
| Antiretroviral Pregnancy Registry (APR) | Teva Pharmaceuticals USA, Inc. | $28.84 | 4 |
| Antiretroviral Pregnancy Registry (APR) | Mylan Inc. | $28.73 | 2 |
| Antiretroviral Pregnancy Registry | West-Ward Pharmaceuticals | $14.46 | 1 |
| Antiretroviral Pregnancy Registry (APR) | Celltrion, Inc. | $12.92 | 1 |
| Antiretroviral Pregnancy Registry (APR) | Lupin Pharmaceuticals, Inc | $11.39 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 75 | 110 | $28,406 | $9,284 |
| 2022 | 4 | 97 | 164 | $28,752 | $13,862 |
| 2021 | 3 | 83 | 139 | $25,359 | $12,041 |
| 2020 | 6 | 120 | 167 | $32,183 | $13,649 |
Total Patients
375
Total Services
580
Medicare Billing
$48,836
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 45 | 72 | $11,878 | $4,717 | 39.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 18 | 18 | $10,548 | $2,591 | 24.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 12 | 20 | $5,980 | $1,976 | 33.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 44 | 85 | $11,900 | $6,122 | 51.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 22 | 22 | $7,150 | $3,479 | 48.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 20 | 37 | $6,882 | $3,078 | 44.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 20 | $2,820 | $1,183 | 41.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 28 | 54 | $9,944 | $4,712 | 47.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 36 | 66 | $9,240 | $4,136 | 44.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 19 | 19 | $6,175 | $3,192 | 51.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 34 | 54 | $7,254 | $3,298 | 45.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 20 | 35 | $6,255 | $3,052 | 48.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 17 | 17 | $5,490 | $2,832 | 51.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 22 | 31 | $6,820 | $2,021 | 29.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 12 | 12 | $3,844 | $1,430 | 37.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 15 | 18 | $2,520 | $1,017 | 40.3% |
About Dr. William Short, MD
Dr. William Short, MD is a Infectious Disease healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1669414827.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Short, MD has received a total of $514,722 in payments from pharmaceutical and medical device companies, with $92,668 received in 2024. These payments were reported across 487 transactions from 23 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($378,785).
As a Medicare-enrolled provider, Short has provided services to 375 Medicare beneficiaries, totaling 580 services with total Medicare billing of $48,836. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Philadelphia, PA
- Active Since 06/12/2006
- Last Updated 08/26/2015
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1669414827
Products in Payments
- DOVATO (Drug) $141,373
- CABENUVA (Biological) $75,855
- PREZCOBIX (Drug) $48,063
- SYMTUZA (Drug) $36,216
- Symtuza (Drug) $34,764
- RUKOBIA (Drug) $32,797
- JULUCA (Drug) $7,000
- Vemlidy (Drug) $2,660
- Veklury (Drug) $1,980
- MK-8591A (Drug) $1,741
- NORVIR (Drug) $1,011
- GENERIC (Drug) $600.80
- Abacavir and Lamivudine (Drug) $98.39
- DARUNAVIR (Drug) $78.58
- Zidovudine (Drug) $43.19
- TRIUMEQ (Drug) $40.29
- ADEFOVIR DIPIVOXIL (Drug) $39.29
- PIFELTRO (Drug) $36.67
- ENTECAVIR (Drug) $14.46
- Fuzeon (Biological) $14.46
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Philadelphia
Judith Wolf, Md, MD
Infectious Disease — Payments: $1.4M
Infectious Disease $1.4M
Karam Mounzer, Md, MD
Infectious Disease — Payments: $802,727
Infectious Disease $802,727
Pablo Tebas, Md, MD
Infectious Disease — Payments: $227,362
Infectious Disease $227,362
Ian Frank, Md, MD
Infectious Disease — Payments: $152,592
Infectious Disease $152,592
Lisa Spacek, M.d, M.D
Infectious Disease — Payments: $100,519
Infectious Disease $100,519
Jay Kostman, Md, MD
Infectious Disease — Payments: $81,312
Infectious Disease $81,312